The National Cancer Institute of America defines cancer as “a disease in which some of the body’s cells grow uncontrollably ...

Fight against cancer starts with understanding that knowledge is not just empowering but a survival tool. This holds for ...

Medically reviewed by Qin Rao, MD Barrett's esophagus occurs when the lining of the esophagus, the tube that runs from the ...

A Midtown-based diagnostics company raised capital in a deal to advance its novel approach to screening for the risk factors ...

Background: Neoadjuvant therapy is widely used for esophageal cancer (EC), but optimal treatment regimens and predictive factors for outcomes remain unclear. This study retrospectively analyzed data ...

Esophageal cancer, particularly esophageal squamous cell carcinoma (ESCC), is one of the most prevalent digestive malignancies, with a 5-year survival rate of only 20%. Although some cancer ...

A bill to provide cancer screenings for firefighters in Utah passed through the Legislature on Wednesday. Shortly thereafter, legislators were joined by firefighters and Gov. Spen ...

Esophageal squamous cell carcinoma accounts for approximately 90% of all esophageal cancer cases. Projections estimate that ...

Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced the ...

The US Food and Drug Administration has approved tislelizumab (Tevimbra, BeiGene), in combination with platinum-containing ...

The FDA has approved Tevimbra (tislelizumab) for use in combination with chemotherapy as first-line treatment for unresectable or metastatic, PD-L1-positive ESCC.

Tislelizumab plus chemotherapy received FDA approval as a frontline therapy for individuals with unresectable or metastatic ...